English (United States)

About the MARITIME-1 study

The MARITIME-1 study is for people living with obesity or who are overweight. In this study, we are exploring if an investigational medicine (a monthly injection) is safe to use, and whether it can help people to lose weight and help manage weight-related health conditions.

Who can take part?

Amgen is currently enrolling for this trial.

You, or someone you care for, may be able to take part if you/they:

  • are 18 years of age or older,
  • have obesity, or
  • are overweight and are living with a weight-related condition, such as hypertension, dyslipidemia, sleep apnea, cardiovascular disease, or metabolic dysfunction-associated steatotic liver disease.

What will this study involve?

The MARITIME-1 study will last up to 88 weeks (a little under 2 years). Participants will receive either the investigational medicine or a placebo, which contains no actual medicine. A placebo looks the same as the investigational medicine.


The study is made up of 3 parts.

Screening period




(up to 4 weeks)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center to see if you meet the requirements of the study

Study treatment period 


(about 72 weeks / 16.5 months)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center about 20 times for assessments
  • Receive the study drug or a placebo

Follow-up period




(about 12 weeks / 3 months)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center once more for study assessments